Crossmark

Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database

Crossref DOI link: https://doi.org/10.1186/s40360-025-00878-3

Published Online: 2025-02-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Shiqiao

Ren, Guizhi

Pan, Heng

Chen, Jiayi

Huang, Jiayu

Mei, Qinghua

Li, Zhongze

Zou, Guosheng
Funding

Funding for this research was provided by:

Scientific Research Fund of Pharmaceutical Society of Guangdong Province (2023KP09)

Medical Science and Technology Research Fund of Guangdong Province (C2022017)
License Information

Text and Data Mining valid from 2025-02-25

Version of Record valid from 2025-02-25
More Information

Article History

Received: 24 September 2024

Accepted: 21 February 2025

First Online: 25 February 2025

Declarations

:

: The FAERS database contains anonymized patient information. The Hospital Ethics Committee has confirmed that ethical approval was not required.

: Not applicable because spontaneous reports of the FAERS are anonymous and publicly available.

: Not applicable because spontaneous reports of the FAERS are anonymous and publicly available.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below